InvestorsHub Logo
Followers 7
Posts 299
Boards Moderated 0
Alias Born 01/07/2010

Re: F1ash post# 196293

Friday, 06/14/2019 9:00:55 PM

Friday, June 14, 2019 9:00:55 PM

Post# of 461360
I'm not 100% sure but I think in blinded trials, while progress & outcome of individual trial arms may be blinded, the progress & outcome of the overall trial is privy to the CRO and by extension, the sponsor but never publicized or acknowledged outside this sphere. This overall data is enough to provide enough information in any trial where a drug provides a differentiated outcome from control.

Not to mention, the PDD trial in Spain has requested a trial extension already. This would not have been done on a whim or gut feeling.

The latest shelf may not be for a stronger hand at the poker table but to fund the Australian PDD & Rett trials which were never part of the original plan through the period Missling kept insisting they were funded for 2yrs out. That & he's made some key hires since.

PDD trial extension request, trial expansion to Australia and some of the hires are clear signals to me of a successful outcome. While study completion dates for Spanish PDD and US Rett is Dec 2019 I expect data as early as late-Oct/early-Nov as the PDD trial was recruiting ahead of schedule and a lot of pre-enrollment ID legwork was completed in Rett for quicker recruitment.

Missling could well commence with his characteristic "breadcrumb trail" purchases in the late summer. I don't think any LPC activity will depress SP too much this time around (barring an overall mkt slump) as the stealth accumulation has begun and all hell will break lose when Missling starts to nibble. Been a loooooonnng-time holder and this is home-stretch.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News